Strand Life Sciences Aims to Expand CancerSpot Test and Reduce Costs

Strand Life Sciences Aims to Expand CancerSpot Test and Reduce Costs

Strand Life Sciences plans to expand its multi-cancer early detection test, <b>CancerSpot</b>, to more hospitals and lower the cost to around ₹10,000. CEO <b>Dr Ramesh Hariharan</b> stated that a four-year study involving 43 hospitals successfully detected cancer using DNA from circulating tumor cells. The non-invasive blood test combines DNA sequencing and artificial intelligence to identify chemical modifications that distinguish cancer cells. The company ultimately aims to make the <b>screening process</b> more accessible across various global markets.

By News Desk • 11/20/2026
Read Full

This page is a shareable card. Download our app to get the full swipe experience!